Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045390 · ClinicalTrials.gov registry record · NA
An App-based Instructional Platform to Improve Eye Drop Recall
A NA study of Glaucoma, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06045390: Completed NA study of Glaucoma, sponsored by University of California, San Francisco.
NCT06045390 is a NA study of Glaucoma that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06045390, a NA study of Glaucoma, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this interventional study is to assess whether an in-office, language-concordant instructional app improves drop regimen recall in a population of glaucoma patients who are on multi-drop regimens. Participants will be divided into two groups -- those who use the app and those who do not. The app will have narrated information regarding the drop regimen, a quiz to test understanding of the regimen, and will enable a graphical printout of the eye drops and schedule. At one month, both groups will be assessed on their eye drop regimen recall.
Primary Outcome
This will be assessed through questions querying which drops the patients are taking, the number of times they are taking each drop, and the laterality of each drop. Each answer/drop will be individual recorded, and then total number of correct answers will be divided by the total number of questions.
Conditions Studied
Interventions
- OTHER App
Study Locations (1)
California
- San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2025-06-01 |
| Phase | NA |
What the finished NCT06045390 record still lists
NCT06045390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which App is the first listed.
NCT06045390 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06045390 about?
NCT06045390 is a clinical study titled "An App-based Instructional Platform to Improve Eye Drop Recall". The goal of this interventional study is to assess whether an in-office, language-concordant instructional app improves drop regimen recall in a population of glaucoma patients who are on multi-drop regimens. Participants will be divided into two groups -- those who use the app and those who do not...
What is the current status of trial NCT06045390?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2024-09-01. Estimated completion is 2025-06-01.
What conditions does trial NCT06045390 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT06045390?
The interventions under investigation include: App (OTHER).
Who is sponsoring clinical trial NCT06045390?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06045390 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06045390's enrollment target sits among peer trials
20 87th of 92 higher than 5 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI